# Nuclide record idea-copper-theranostic-pair-standard (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-copper-theranostic-pair-standard/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-copper-theranostic-pair-standard" ;
  schema:name "A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment"@en ;
  schema:description "Most PSMA treatments use one molecule to take the pre-treatment scan and a slightly different molecule for the actual treatment, so the scan is only an approximate guide. A copper-based pair uses the identical molecule for both steps, just with a different form of copper, so the scan should be a much truer preview of where the treatment radiation will go."@en ;
  schema:url <https://nuclide.cc/ideas/idea-copper-theranostic-pair-standard/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.claritypharmaceuticals.com/news/secure-update-05-08-26/>, <https://www.claritypharmaceuticals.com/news/secure-undetectable/>, <https://clinicaltrials.gov/study/NCT04868604> ;
  nuclide:tag "copper theranostics", "prostate", "same-molecule imaging" ;
  nuclide:related <https://nuclide.cc/trials/nct04868604/>, <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/cu-64/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/cu-67/> .